Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
luxeptinib (CG-806) / Aptose Biosci
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas	Terminated	1	36	US	CG-806, Luxeptinib	Aptose Biosciences Inc.	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma	05/24	05/24
NCT04477291: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS	Terminated	1	45	US	CG-806	Aptose Biosciences Inc.	Acute Myeloid Leukemia, Myelodysplastic Syndromes	04/24	04/24